Study Finds Patients With Cancer Are Less Likely to Die of Opioid Overdose

Publication
Article
Oncology Live®Vol. 20/No. 2
Volume 20
Issue 2

Despite changes affecting how oncologists prescribe and manage opioid use among their patients, there are few data analyzing the frequency and extent to which patients with cancer die of opioid overdoses.

Fumiko Chino, MD

Fumiko Chino, MD

Despite changes affecting how oncologists prescribe and manage opioid use among their patients, there are few data analyzing the frequency and extent to which patients with cancer die of opioid overdoses.

Fumiko Chino, MD, a radiation oncologist at Duke University School of Medicine in Durham, North Carolina, set out to shed some light on this poorly understood aspect of the opioid epidemic. She and 2 colleagues at Duke used National Center for Health Statistics death certificate data to create a dataset that included all US deaths for which opioid overdose was listed as the primary cause of death during a 10-year period.

The investigators then analyzed death certif-icates for people who had fatal overdoses but also listed cancer as a contributing cause of death. They calculated the opioid death incidence from the estimated cancer survivor population and the US population as a whole.

Chino, who presented the data at the 2018 ASCO Quality Care Symposium, reported that there were 895 opioid-related deaths in patients with cancer between 2006 and 2016. This compares with 193,500 such deaths in the US population as a whole.

Notably, the incidence rates of opioid deaths increased during that time in both populations, but the increase was much lower among patients with cancer. In the general population, opioid deaths rose from 5.33 to 8.97 per 100,000 people (P <.001). In the cancer population, opioid deaths increased from 0.52 to 0.66 per 100,000 people (P <.001) during the same 10-year period.

For Chino, these results provide reassurance that opioid-related deaths in the cancer population are much rarer than in the general population. At the same time, there is cause for concern, she said: “Even though our population’s overdose risks were proportionately lower than the general public’s, the numbers of fatal overdoses are still rising over time.”

William Dale, MD, PhD, who helped organized the Quality Care Symposium, said that Chino’s research was a strong addition to the symposium. “We know that studies based on death certificate data are limited by the subjectivity of the physician who fills out each death certificate, but Dr Chino took a methodologically appropriate approach to begin to get answers on whether our patients are more or less vulnerable to opioid over-dose than the general population,” he said. “We now have solid evidence to suggest that people with cancer are at a lower risk of death related to opioid use than the general popula-tion, which is important information for us as prescribers.”

Chino CL, Kamal AH, Chino JP. Opioid associated deaths in patients with cancer: a population study of the opioid epidemic over the past 10 years. Presented at: 2018 ASCO Quality Care Symposium; September 28-29, 2018; Phoenix, AZ. Abstract 230. meetinglibrary.asco.org/record/166352/abstract

Related Videos
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
Video 4 - "Predisposition for Patients Developing DTC: Age and Gender"
Video 3 "Determining Prognosis for Patients with Differentiated Thyroid Cancer"
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic